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Abstract
Subacute sclerosing panencephalitis (SSPE) is a rare, slowly progressive neurological disorder
caused by the persistent infection with measles virus (MV). Despite much research into SSPE, its
pathology remains obscure. We examined autopsy tissues of eight SSPE patients by real time
quantitative PCR, immunohistochemistry and immunoblotting to determine viral load. MV N, M
and H gene RNA could be detected in the central nervous system (CNS) of all patients and in two
non-CNS tissues of one patient. The viral burden between patients differed up to four-fold by
quantitative PCR and corresponded with detection of MV protein. The level of both viral RNA and
antigen in the brain may correlate with disease progression.
Background
Subacute sclerosing panencephalitis (SSPE) is a rare,
slowly progressive neurological disorder of children and
young adults, caused by the persistent infection with mea-
sles virus (MV). After acute infection with MV, typically at
a very young age, the patients appear to recover normally.
Following a period of asymptomatic persistence, usually 3
to 10 years, neural dysfunctions develop and progress
over months to years, resulting eventually in coma and
death. Although much effort has gone into researching
SSPE, its pathology remains largely obscure. The progres-
sion of SSPE greatly differs in individual patients [1].
What causes a rapid deterioration within months or slow
progression over several years (4+) remains an unresolved
question.
Viral load has been correlated to disease development,
progression and outcome in several infections, including
HIV, SIV, cytomegalovirus [2,3] and Epstein-Barr virus [4].
Occurrence of cognitive impairment in HIV infected
patients and development of SIV encephalitis in
macaques was linked to the level of viral RNA in the cere-
brospinal fluid (CSF). In contrast, CNS disease did not
correlate with plasma viral load in either HIV or SIV [5-7].
No studies have been carried out so far trying to relate the
progression of SSPE with viral load. Due to the rarity of
the condition and the invasiveness of removing biopsy
samples, obtaining information on viral load during the
course of disease is problematic. However, the use of
autopsy samples may provide some insight into this rela-
tionship.
As MV can usually be detected in brain tissue from biopsy
or autopsy by RT-PCR and/or immunohistochemistry, it is
thought to persist and spread within the CNS. Although
the brain appears to be the main location of persistent MV
in SSPE, it is not entirely clear if this is also the site of per-
sistence and the only target during disease. Viral antigen
or RNA have been detected outside the CNS in SSPE cases
[8-10]. To address the question of MV persistence outside
the CNS in SSPE, we included available peripheral tissues
of two SSPE patients in our analysis.
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This study was carried out to determine whether differ-
ences in viral load caused diversity of disease progression.
Autopsy tissues of brain and non-brain origin of eight
confirmed cases of SSPE were analysed by quantitative
PCR to determine amounts of the MV RNAs encoding the
nucleoprotein (N), matrix protein (M) and haemaggluti-
nin (H) and by immunological techniques to detect the N
protein.
Results
Patients and samples
Autopsy or biopsy tissues of eight SSPE patients were ana-
lysed, details are shown in Table 1. All cases have been
clinically and serologically confirmed as SSPE and MV
RNA could be detected by RT-PCR in brain samples. Non-
CNS tissues were available in two cases, liver, spleen and
kidney of patient UK111, and liver, spleen, heart, lymph
node, thymus, appendix and terminal ileum of UK98. All
patients have been described previously [9,11].
Detection of MV RNA
MV N gene RNA was detected by quantitative real time
PCR (qPCR) in all available CNS tissues from eight SSPE
patients and in two non-CNS tissues of one patient. The
concentration of MV N gene RNA in CNS tissues ranged
from almost 2 × 106 copies of N RNA per ng total RNA in
occipital brain patient UK111 to 4 × 102 copies/ng RNA in
temporal brain of case UK585, respectively. In addition to
relating copy numbers to the amount of total RNA, they
were standardised as a function of GAPDH mRNA.
GAPDH (glyceraldehyde-3-phosphate-dehydrogenase) is
a ubiquitously expressed message, which is frequently
used to standardise across tissues. Although expression of
GAPDH may not be uniform across all tissue types, this
method was found acceptable in a comparison of nine
CNS and non-CNS tissues from three SSPE patients. The
maximum fold change between CNS tissues was <8-fold,
between CNS and non-CNS tissues <11-fold (Table 3).
Expressed as units MV RNA per units GAPDH mRNA
(%GAPDH) MV N RNA copy numbers in the CNS of the
eight patients ranged from 6 × 103 %GAPDH in patient
UK111 to <1% GAPDH in patient UK585. The only posi-
tive non-CNS tissues were thymus and appendix from
patient UK98. In the thymus sample approximately 25
copies/ng RNA or 12% GAPDH were detected, in appen-
dix 85 copies/ng RNA or 10% GAPDH. Results are shown
in Figure 1 as copies per ng total RNA and as percentage of
GAPDH RNA, except for samples from patients UK85,
Table 1: Samples.
Case Gender Available samples Age at disease onset Duration of 
persistence (acute MV 
to SSPE onset)
Duration of disease 
(SSPE onset to death)
UK111 F Occipital brain 15 years 9–15 years 4 months
Heart
Lung
Liver
Spleen
UK98 M Frontal brain 10 years 5–8 years 60 months
Parietal brain
Occipital brain
Temporal brain
Cerebellum
Lymph node
Thymus
Heart
Lung
Spleen
Liver
Kidney
Tonsil
Appendix
Terminal ileum
UK585 F Frontal brain 24 years 19 years 18 months
Temporal brain
UK83 M Brain 12 years 11 years 17 months
UK85 M Brain 15 years 11 years 6 months
UK88 M Brain 17 years 12 years 3 months
UK86 F Brain 10 years 5 years1 34 months
UK87 M Brain 7 years 5 years1 35 months
1Biopsy tissues were taken at disease onset.Virology Journal 2006, 3:49 http://www.virologyj.com/content/3/1/49
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UK88, UK86 and UK87. These results are only shown as
%GAPDH, as RNA was not concentrated enough to be
quantified. Where both normalisation methods were
available, similar relative results were obtained with both.
MV N RNA positive samples were also used for detection
of MV M and H gene RNA. The H gene PCR lead to very
similar results as the N gene PCR, both in copy numbers
and %GAPDH. Occipital brain tissue of UK111 contained
just under 2 × 106 copies of H RNA per ng total RNA.
Again the weakest positive CNS sample was temporal
brain of UK585 with just under 2 × 103 copies/ng RNA.
This is approximately 9 × 103 %GAPDH and 3% GAPDH,
respectively. The M gene signal was approximately ten-
fold weaker, but the different cases were similar in relation
to each other as with the N and H genes. Occipital brain
of UK111 contained 4 × 105 copies M gene/ng RNA or 3 ×
102 %GAPDH. This gene could not be detected in tempo-
ral brain tissue of patient UK585. In PCRs with MV N, M
and H gene targets, occipital brain of UK111 was the
strongest positive when looking at copies/ng RNA, while
the brain of UK85 contained most MV RNA when
expressed as a function of GAPDH. The efficiency of all
three PCR reactions was found to be similar when titra-
tions of p(+)MV, a MV genome containing plasmid, were
used as template (data not shown), which indicates that
the numbers obtained with the different PCRs can be
compared. The M and H gene results confirm the relative
findings with the N gene. All quantities are illustrated in
Figure 1.
Detection of MV protein
To determine whether the detected viral RNA is actively
replicating, immunological methods were used to visual-
ise MV protein in tissues from patients UK111, UK98 and
UK585. In occipital brain tissue of UK111, a large number
Detection of MV RNA by quantitative PCR in SSPE tissue samples Figure 1
Detection of MV RNA by quantitative PCR in SSPE tissue samples. N (A), M (B) and H (C) RNA are shown and expressed as 
copy per ng total RNA and as percentage of detected GAPDH RNA. Values <1 were converted to 1 before logarithmic trans-
formation. The results of one experiment are shown, representative for two with M an H genes and 3 with N gene. The error 
bars indicate 95% confidence intervals of duplicate samples.
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of MV N protein positive cells could be detected by immu-
nohistochemistry, as seen in Figure 2. This staining of pro-
tein was not observed when an antibody against rubella
virus was used. No MV N specific staining was located in
any of the brain tissues of UK98 and UK585. There was no
evidence of MV protein in any of the non-CNS tissues.
To detect MV protein with higher sensitivity, tissue lysates
were analysed by immunoblotting (Figure 3). In agree-
ment with the findings using immunohistochemistry, a
strong signal could be observed at 58 kDa in occipital
brain of UK111. Additionally, N protein was also detected
in the parietal and occipital brain tissues of UK98, and
weakly in the frontal and temporal brain tissues of the
same patient. A previously reported 45 kDa degradation
product of N protein could also be seen in all samples
with the 58 kDa band [12]. A weak band at 45 kDa was
present in the lane containing the sample derived from
cerebellum of UK 98, which may indicate low level of
infection. No MV N protein could be detected in the fron-
tal brain of UK585 or any of the non-CNS samples. It was
essential not to remove cell debris by centrifugation after
homogenisation and lysis, as this step lead to loss of
bands in all samples from patient UK98 and reduced the
band intensity of the strong band from brain tissue of
UK111. This suggests that N protein aggregates and may
bind to MV RNA or cellular RNA. These aggregates are
large enough to be removed by centrifugation at 11,300 ×
g for 5 min.
Disease progression, viral burden and MV M gene 
expression
A weak inverse correlation between viral loads measured
by qPCR and SSPE disease duration was detected. Quanti-
ties of viral RNA were compared to durations of SSPE and
of infection from primary MV acquisition to sample date.
Results are shown in Figure 4. While there was no correla-
tion between quantity of MV RNA and total duration of
infection, viral burden and SSPE duration may be linked.
In patients where high load of viral RNA was measured
and MV protein detected (UK111 and UK85), SSPE pro-
gressed rapidly and the patients died within four and six
months of disease onset, respectively. The high viral bur-
den may have accelerated the course of disease. Two sub-
jects did not exhibit this tendency. In patient UK98, with
intermediate viral load, disease progressed extremely
slowly over 60 months. In UK88 on the other hand, very
low levels of infection were detected but the patient died
within three months of disease onset.
To investigate a possible link between virus integrity and
viral spread, MV loads detected here were compared with
the extent of MV M gene and protein mutation reported
previously [11]. In cases UK111 and UK85 the MV M pro-
teins contained few substitutions and a high virus load of
6 × 103 and 1 × 105 %GAPDH, respectively, was detected.
The M gene of virus in case UK585, on the other hand, was
strongly mutated and low virus levels of <1% GAPDH
were measured. In case UK83, however, viral load was
high (1 × 103 %GAPDH), despite presence of virus with a
highly mutated M protein.
By Spearman's ranked correlation, no statistically signifi-
cant links were found between viral load, duration of dis-
ease or infection and number of total or expressed
mutations in the M gene of the isolated viruses.
Discussion
Great variation in levels of MV RNA and protein were
detected in different SSPE patients, while findings with
quantitative PCR and immunological methods are in
agreement. In the occipital brain of UK111, 2 × 106 copies
of MV N RNA could be detected per ng total RNA, approx-
imately 100 times more than in the brain samples of
UK98. The brain of UK111 was the only analysed tissue
positive by immunohistology and was a much stronger
positive by immunoblotting than specimens from UK98.
In the brain of UK585, which was negative by immunob-
lotting, only 4 × 102 to 2 × 103 copies could be detected.
Thymus and appendix of UK98 were the only non-CNS
samples positive for the N gene by real time PCR. GAPDH
normalisation of these samples may be less reliable due to
greater heterogeneity of tissue origin. However, taking
into account exclusively the copy numbers per total RNA,
they were weak positives, contained fewer than 102 copies
per ng RNA.
A weak correlation between the amount of MV RNA and
the duration of SSPE was observed. As some CNS samples
contained relatively little MV RNA, high viral load alone
did not seem to be responsible for death, but may have
accelerated destruction of tissue. MV specific interferon-
gamma release by host immune cells may determine dis-
ease progression [13]. It is feasible that release of high lev-
els of interferon restricts viral growth and so reduces viral
load and the speed of disease progression. Additionally,
treatment with interferon or other antiviral agents during
the course of SSPE may influence viral replication. Unfor-
tunately, treatment history of the patients was not known
and could therefore not be taken into account.
As the MV genome is encoded in RNA, PCR detection does
not distinguish between genomic and mRNA. It is there-
fore not known if the identified virus is actively tran-
scribed, but presence of MV protein indicates that the
virus is transcribed. However, it is not clear whether a
larger number of MV RNA copies indicate a greater
number of infected cells or greater number of MV RNA
copies per infected cell. Increased MV RNA levels per cell
may indicate a more actively replicating virus, which mayVirology Journal 2006, 3:49 http://www.virologyj.com/content/3/1/49
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Detection of MV N protein by immunohistology Figure 2
Detection of MV N protein by immunohistology. CNS tissue samples of three patients were analysed, and non-CNS tissues of 
two of them. The following sections are shown here. (A, B) UK111, brain. (C) UK98, frontal lobe. (D) UK98, parietal lobe. (E) 
UK98, occipital lobe. (F) UK98, temporal lobe. (G) UK585, frontal lobe. (H) UK585, temporal lobe. Original magnification 10 
×, unless otherwise indicated.Virology Journal 2006, 3:49 http://www.virologyj.com/content/3/1/49
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Relationship between viral load, disease duration and M gene substitutions Figure 4
Relationship between viral load, disease duration and M gene substitutions. Linear correlation of log10 of viral load with (A) dis-
ease duration (●) and persistence from initial infection to sample date () or (B) number of amino acid (●) and nucleotide 
() substitutions in the MV M gene. R2 values are indicated for each correlation. For patients UK98 and UK111, where length 
of persistence is not precisely known, an average was calculated from shortest and longest possible duration of persistence.
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Detection of MV N protein in tissue samples by immunoblotting Figure 3
Detection of MV N protein in tissue samples by immunoblotting. Tissues were homogenised, lysed and protein denatured, 
before separating equal amounts of total protein by SDS-PAGE, Western blot analysis with a MV N specific antibody and 
chemiluminescent detection. M: weight marker.
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uses faster progressing disease. Alternatively, infection of
a greater number of cells may lead to destruction of more
tissue, which may also lead to accelerated disease.
Of patient UK98, tissues from five brain areas, frontal,
parietal, occipital, temporal lobes and cerebellum, were
available for analysis. Virus levels in the cerebrum – fron-
tal, parietal, occipital and temporal lobes – were within a
factor of 3.5, which may indicate that the virus did not
favour any one particular area. Alternatively this may be
an indication of very slow disease progression, as is the
case in this patient, during which the virus had sufficient
time to spread into all regions. In contrast, infection of the
cerebellum was 30 to 100 times lower. The cerebellum is
a very extensively connected part of the brain, which inte-
grates information from the cerebrum as well as the
periphery. Both efferent and afferent pathways link it to
the cerebrum. Lack of axonal connection does therefore
not cause this lower level of infection. It may rather be the
different cell types present within this organ. The cerebel-
lar neurons, the granule cells, may be less susceptible to
MV infection.
The detection of MV RNA in non-CNS tissues was very
low, which indicated that these tissues were not reservoirs
of infection. The detected RNA may have derived from
infiltrating lymphocytes that were infected within the
CNS. Peripheral lymphocytes of individuals with SSPE
have been shown to contain MV [14]. Alternatively, the
source of MV sequences may have been contamination
during autopsy. No information was available on the
exact autopsy procedures, contamination could therefore
not be ruled out.
In summary, the amount of MV protein and RNA differs
greatly in different cases of SSPE, which may influence
progression of the disease. Further studies of greater num-
bers of cases are required to confirm these findings.
Table 3: Expression of housekeeping genes in tissues of SSPE patients.
Patient Tissue GAPDH
(104 copy eqivalents/5 ng 
RNA)
Beta-actin
(104 copy eqivalents/5 ng 
RNA)
18S rRNA
(104 copy eqivalents/5 ng 
RNA)
UK98 Frontal brain 1.95 3.28 70.16
Parietal brain 0.69 1.82 25.24
Occipital brain 1.75 1.07 51.19
Temporal brain 4.93 6.41 84.17
Thymus 3.43 2.48 0.20
Appendix 7.09 3.38 0.74
Ileum 1.54 1.26 1.07
UK111 Occipital brain 1.46 3.51 83.00
UK585 Frontal brain 0.90 2.63 87.17
Table 2: Primer sequences used for the amplification of MV and housekeeping genes with amplicon length.
Gene (GenBank accession number) Primer sequence 5'-3' Expected amplicon length
MV N CAA GAC CCT GAG GGA TTC AA
GTT CCT CAC CAC ATC CAA CC
192 bp
MV M TGT TAC CCG CTG ATG GGT AT
TTC TGG CTG TCA TTG TGA GG (M3'-1R, Jin 2002)
223 bp
MV H ATC AGG GAT CAG GGA AAG GT
CAT TCG CAA CTT GTC ATC TG (Mh4, Jin 1998)
206 bp
GAPDH (NM_002046) GAG TCA ACG GAT TTG GTC GT
TTG ATT TTG GAG GGA TCT CG
238 bp
beta-actin (NM_001101) GGA CTT CGA GCA AGA GAT GG
AGC ACT GTG TTG GGC GTA CAG
234 bp
18S rRNA (X03205) CAT GGC CGT TCT TAG TTG GT
CGC TGA GCC AGT CAG TGT AG
218 bp
GAPDH = glyceraldehydes-3-phosphate dehydrogenase, bp = base pairsVirology Journal 2006, 3:49 http://www.virologyj.com/content/3/1/49
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Materials and methods
Real time PCR
Tissues were homogenised and total RNA extracted with
RNeasy Mini kit (Qiagen, UK). RNA was treated with
DNase to avoid amplification of genomic DNA. The con-
centration of extracted RNA was determined by spectro-
photometry and 100 ng RNA reverse transcribed using
random primers. PCR primers were designed using
Primer3 software [15] to yield a 192, 223, 206, 238, 234
and 218 base pair amplification fragment of MV N, M or
H gene, human GAPDH, beta-actin and 18S rRNA, respec-
tively, and, where possible, read across intron/exon junc-
tions to avoid amplification of genomic DNA (Table 2).
PCR was performed in a reaction containing 5 μl RT prod-
uct, 12.5 μl Platinum® SYBR® Green qPCR SuperMix UDG
(Invitrogen, UK), 0.2 μM of each primer and 6.5 μl nucle-
ase free water, using a Rotor-Gene 3000 (Corbett
Research, UK) with the following cycling conditions.
Hold at 50°C for 2 min, hold at 95°C for 3 min, followed
by 45 cycles of 95°C for 15 sec, 55°C for 30 sec, 72°C for
30 sec. Data was acquired at 72°C during each cycle with
excitation wavelength of 470 nm and detection at 585
nm. Amplification was followed by melt analysis from
50–90°C. All samples were run as duplicates and analysed
using Rotor-Gene 6.0.7 software. Integrity of all samples
was demonstrated by amplification of GAPDH mRNA.
DNA and RNA standards were included in each run and
each reaction was performed in duplicate. For verification
of correct amplification, PCR products were run on agar-
ose gel and sequenced.
Real time PCR controls
DNA and RNA standards were used for qPCR and RT-
qPCR, respectively. The concentration of a plasmid con-
taining the entire MV genome, p(+)MV (kindly provided
by M. Billeter, University of Zürich), was determined by
spectrophotometry. A ten-fold dilution series was made
and used as DNA standard. From this plasmid, the whole
N, M and H genes were amplified by PCR and cloned into
pGEM (Promega, UK). The pGEM plasmid was linearised
with SpeI and the MV fragments transcribed in vitro using
the T7 Riboprobe System (Promega, UK) according to the
manufacturer's instructions. The resulting RNA was puri-
fied and the concentration determined by spectropho-
tometry. Ten-fold dilution series were made and included
in the RT reactions as RNA standards.
In order to compare results from different tissues and cor-
rect for use of different numbers of cells in each sample,
two normalisation methods were employed. First, the
same concentration of total isolated RNA was used for
each RT-PCR. This lead to results expressed as copies of
MV RNA per ng total RNA input. Alternatively, a house-
keeping gene was employed to compare RNA levels
between different samples. To find an appropriate gene to
normalise sample input, 5 ng RNA from nine samples
were used for qPCR with primers against all three house-
keeping genes, beta-actin, GAPDH and 18S rRNA. Results
are shown in Table 3. Both beta-actin and GAPDH were
found to be suitable for normalisation, GAPDH was used
in subsequent experiments. Results are expressed as units
MV RNA/units GAPDH mRNA × 100 = amount MV RNA
in %GAPDH.
Immunohistochemistry
Formalin fixed, paraffin embedded tissues were analysed
by immunohistochemistry. The method used by
McQuaid et al. [16] was modified as follows. Formalin
fixed, paraffin embedded 7 μm thick tissue sections on
silane-coated slides were hydrated in xylene and alcohol.
Endogenous peroxidase activity was blocked by 10 min
incubation in 3% H2O2 in methanol. Tissues were washed
in water and blocked in blocking solution (1:20 dilution
of normal rabbit serum in PBS-T (0.1% Tween-20 in
PBS)) for 10 min. Sections were incubated with a mono-
clonal mouse antibodies against the N protein (clone
7C11, [17]) at a dilution of 1:2000 in blocking solution
overnight at 4°C, washed in PBS-T and incubated with a
biotin conjugated secondary antibody (Dako, UK) at
1:400 in blocking solution for 1 hr. After further washing,
streptavidin coupled HRP (Dako, UK) was added for 30
min, tissues washed and incubated with DAB, followed by
haematoxylin counterstaining.
Immunoblotting
Tissues were homogenised in lysis buffer (50 mM Tris,
150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 1% Triton X-
100 and added protease inhibitors) and protein concen-
trations of whole lysates, without removal of cell debris,
determined by spectrophotometry. Equal amounts of
total protein of each sample were analysed by SDS-PAGE
and immunoblotting. The 7C11 MV N specific antibody
was used to probe the blots, followed by detection with an
anti-mouse-HRP antibody (Dako, UK) and ECL plus rea-
gents (Amersham Bioscience, UK).
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